Gastrointestinal Adverse Events

Gastrointestinal Adverse Events

Gastrointestinal adverse events (GI AEs) are the most frequently reported side effects associated with GLP-1 receptor agonists and related incretin-based therapies. These events include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. They arise primarily from GLP-1 receptor-mediated slowing of gastric emptying and central nervous system effects on nausea and satiety pathways. GI AEs are typically most pronounced during the initial weeks of treatment and during dose escalation periods, with the majority being mild to moderate in severity.

The management of GI AEs is a critical aspect of clinical practice with incretin-based therapies. Gradual dose escalation protocols are specifically designed to allow the gastrointestinal tract to adapt to increasing drug exposure, thereby reducing the incidence and severity of these events. Dietary modifications—such as eating smaller meals, avoiding high-fat foods, and staying hydrated—can also help mitigate symptoms. In clinical trials, GI AEs are the most common reason for treatment discontinuation, making tolerability a key differentiator among competing therapies.

In retatrutide Phase 2 trials, GI AEs followed the expected class pattern: nausea was the most commonly reported event (affecting up to 26% of participants at higher doses), followed by diarrhea (18%) and vomiting (13%). These events were dose-dependent, generally transient, and largely resolved with continued treatment and dose escalation. Severe GI AEs were rare (<1%), and discontinuation rates due to gastrointestinal intolerance were low. The Phase 3 TRIUMPH program uses an optimized dose escalation schedule designed to further minimize GI-related discontinuations while maintaining the full therapeutic benefit of higher dose levels.